Showing 2821-2830 of 5258 results for "".
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based
- Can IL-33 Blockade Ease Severe Poison Ivy Itch? Mouse Study Says Maybehttps://practicaldermatology.com/news/can-il-33-blockers-ease-severe-poison-ivy-itch/2458382/Blocking interleukin 33 (IL-33) may put the brakes on the uncontrollable itch caused by poison ivy, poison sumac, poison oak and even mango trees, according to a mouse study conducted by scientists at Duke Health in Durham, NC, and Zhejiang Chinese Medical University in China. The r
- FDA OKS Santalis' Phase 2 Study of EISO For ADhttps://practicaldermatology.com/news/fda-oks-santalis-phase-2-study-of-eiso-in-ad/2458385/The U.S. Food and Drug Administration (FDA) has green lighted Santalis Pharmaceuticals Phase 2 clinical study of East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability stu
- The Election and The Marketshttps://practicaldermatology.com/news/the-election-and-the-markets/2458392/By David Mandell, JD, MBA and Robert Peelman, CFP® This presidential race is seemingly generating more interest, expressions of concern, and questions from clients than past elections. Some clients want to know how the election impacts our investment views and how we might ad
- Oral Nalbuphine®ER Performs Well in Phase 2 Trial of Prurigo Nodularishttps://practicaldermatology.com/news/oral-nalbuphineer-performs-well-in-from-phase-2-trial-in-prurigo-nodularis/2458403/Trevi Therapeutics, Inc.’s Oral Nalbuphine®ER reduced itch intensity and improved quality of life in prurigo nodularis patients, according to a Phase 2 Trial. Nalbuphine ER is an oral extended release mu receptor an
- Encore Dermatology Introduces HylatopicPlus® Lotionhttps://practicaldermatology.com/news/encore-dermatology-introduces-hylatopicplus-lotion/2458402/Encore Dermatology, Inc. is expanding its line to with HylatopicPlus® Lotion in a 14 oz. bottle with pump dispenser. The Rx product relieves the burning, itching and pain experienced with various types of skin conditions, includi
- Indoor Tanners Exhibit Poor Outdoor Sun Protection Practices Toohttps://practicaldermatology.com/news/indoor-tanners-exhibit-poor-outdoor-sun-protection-practices-too/2458406/Adults who frequently tan indoors aren’t great about protecting their skin outdoors or undergoing skin cancer screening either, according to a new study published online by JAMA Dermatology.
- Eau Thermale Avène Launches #AveneHope for Eczema Awareness Monthhttps://practicaldermatology.com/news/eau-thermale-avne-launches-avenehope-for-eczema-awareness-month/2458411/Eau Thermale Avène is launching their #AveneHope program in recognition of Eczema Awareness Month this October. As part of the program, Avè
- Ditch the Itch: EpiCeram Helps Relieve Eczema Symptomshttps://practicaldermatology.com/news/ditch-the-itch-epiceram-helps-relieve-eczema-symptoms/2458431/A new survey from PuraCap Pharmaceutical sheds light on the emotional and physical effects of eczema, a pervasive condition that affects 31.6 million people in the US. According to the survey, a large number of people are not getting the relief they need
- Save the Date: Sept 28th Marks First Ever PsA Awareness Dayhttps://practicaldermatology.com/news/save-the-date-sept-28-is-first-psa-awareness-day/2458433/September 28th marks the first-ever Psoriatic Arthritis (PsA) Awareness Day. Launched by Celgene Corporation and the National Psoriasis Foundation (NPF), PsA Awareness Day is dedicated to education, empowerment, and action for the PsA community. PsA patients can